Jefferies lowers Metagenomi stock price target to $9 from $21 on pipeline timing

Investing.comTuesday, November 18, 2025 at 10:19:30 AM
Jefferies lowers Metagenomi stock price target to $9 from $21 on pipeline timing
  • Jefferies has lowered the stock price target for Metagenomi from $21 to $9 due to concerns regarding the timing of the company's pipeline developments. This significant reduction indicates a shift in market sentiment and raises questions about Metagenomi's ability to deliver on its projected timelines.
  • The lowered price target suggests that investors may need to reassess their expectations for Metagenomi's growth and profitability. Delays in the pipeline could hinder the company's competitive position and impact investor confidence, potentially leading to further stock price volatility.
— via World Pulse Now AI Editorial System

Was this article worth reading? Share it

Recommended Readings
Schrödinger at Jefferies London: Strategic Shift Towards R&D Focus
NeutralFinancial Markets
Schrödinger announced a strategic shift towards a greater focus on research and development during its presentation at the Jefferies London conference. The company aims to enhance its capabilities in drug discovery and development, aligning its operations with evolving market demands.
Doordash upgraded as Jefferies says it is set to under-promise and over-deliver
PositiveFinancial Markets
Doordash has received an upgrade from Jefferies, which indicates that the company is expected to under-promise and over-deliver in its future performance. This positive sentiment reflects confidence in Doordash's ability to exceed market expectations and improve its operational efficiency.
Alnylam at Jefferies London: Strategic Momentum and Future Goals
NeutralFinancial Markets
Alnylam presented its strategic momentum and future goals at the Jefferies London conference, highlighting its commitment to innovation and growth in the biopharmaceutical sector. The company aims to enhance its market presence and operational efficiency while navigating current market dynamics.
Stevanato Group at Jefferies London Healthcare: Strategic Growth in Pharma
NeutralFinancial Markets
Stevanato Group presented its strategic growth initiatives at the Jefferies London Healthcare Conference. The company emphasized its commitment to expanding its market presence and enhancing operational efficiency in the pharmaceutical sector. This presentation reflects Stevanato's focus on innovation and adaptability in a competitive landscape.
MannKind at Jefferies London Healthcare Conference: Strategic Growth Insights
NeutralFinancial Markets
MannKind presented its strategic growth insights at the Jefferies London Healthcare Conference. The company discussed its plans to enhance market presence and develop innovative solutions in the healthcare sector. This presentation reflects MannKind's commitment to advancing its operational strategies and addressing industry challenges.
Inotiv at Jefferies London: Strategic Growth Amid Challenges
NeutralFinancial Markets
Inotiv presented its strategic growth initiatives at the Jefferies London conference, addressing the challenges faced in the current market environment. The company outlined its plans to enhance its market presence and develop innovative solutions to meet evolving demands. This presentation reflects Inotiv's commitment to navigating obstacles while pursuing growth opportunities in the competitive landscape.
Jefferies raises Kanzhun stock price target to $25 on earnings beat
PositiveFinancial Markets
Jefferies has raised its stock price target for Kanzhun to $25 following a positive earnings report that exceeded expectations. This adjustment reflects confidence in Kanzhun's financial performance and growth potential in the market. The increase in the price target is seen as a positive indicator for investors looking for opportunities in the tech sector.
Home Depot stock price target lowered to $438 from $474 at Jefferies
NeutralFinancial Markets
Jefferies has lowered its stock price target for Home Depot from $474 to $438. This adjustment reflects the firm's response to ongoing market conditions and the company's performance. The downgrade indicates a cautious outlook as Home Depot navigates challenges in the housing market and consumer spending.